Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

ClinicalTrials.gov ID: NCT05266586

Public ClinicalTrials.gov record NCT05266586. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.

Study identification

NCT ID: NCT05266586
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: NewAmsterdam Pharma; Industry
Enrollment: 119 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 9, 2022 (Actual)
Primary completion: Aug 12, 2022 (Actual)
Completion: Sep 8, 2022 (Actual)
Last update posted: Jul 3, 2024

2022

United States locations

U.S. sites: 16
U.S. states: 10
U.S. cities: 16

Facility	City	State	ZIP	Site status
Velocity Clinical Research - Westlake d.b.a National Research Institute	Los Angeles	California	90057	—
Valley Clinical Trials, Inc.	Northridge	California	91325	—
Ocala Cardiovascular Research	Ocala	Florida	34471	—
A & R Research Group, LLC	Pembroke Pines	Florida	33024	—
Progressive Medical Research	Port Orange	Florida	32127	—
Meridian Clinical Research - Savannah, GA	Savannah	Georgia	31406	—
Velocity Clinical Research	Meridian	Idaho	83642	—
Biofortis, Inc	Addison	Illinois	60101	—
Northwest Heart Clinical Research, LLC	Arlington Heights	Illinois	60005	—
Midwest Institute for Clinical Research	Indianapolis	Indiana	46260	—
Research Integrity LLC	Owensboro	Kentucky	42303	—
Oakland Medical Research Center	Troy	Michigan	48085	—
Mercury Street Medical	Butte	Montana	59701	—
Meridian Clinical Research- Springdale, OH	Cincinnati	Ohio	45219	—
Aventiv Research, Inc.	Columbus	Ohio	43213	—
Summit Research Group, LLC	Munroe Falls	Ohio	44240	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05266586, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 3, 2024 · Synced Oct 25, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05266586 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →